{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "",
          "alt": "",
          "position": ""
        },
        "variant_string_id": "PARK2"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper discusses somatic mutations of the PARK2 gene, which is associated with Parkinson's disease. The mutations in PARK2 are implicated in glioblastoma and other cancers through loss of protein function.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the role of PARK2 mutations in cancer progression via loss of function."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses cell viability assays and anchorage-independent growth assays to assess the functional impact of PARK2 mutations.",
          "judgment": "Yes",
          "reasoning": "These assays are relevant for assessing cancer progression, which aligns with the disease mechanism defined in Step 1."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The paper does not explicitly describe basic controls (e.g., normal/negative and abnormal/positive) for these assays.",
          "judgment": "No",
          "reasoning": "Basic controls are missing, but the assay is broadly accepted in the field."
        },
        {
          "step_name": "Sub-step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The use of cell viability and anchorage-independent growth assays is a standard approach in cancer research.",
          "judgment": "Yes",
          "reasoning": "These assays are validated historical methods in the field."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "No specific variant controls (known pathogenic or benign) are mentioned for PARK2 mutations in this study.",
          "judgment": "No",
          "reasoning": "Variant-specific controls are not used."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper does not provide statistical analyses or OddsPath calculations for the functional data.",
          "judgment": "No",
          "reasoning": "Statistical sufficiency is lacking."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The number of benign/pathogenic controls used in the study is not explicitly stated.",
          "judgment": "No",
          "reasoning": "Insufficient data on control variants."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    }
  ]
}